Cargando…
SLE - Rituximab in lupus
B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled tr...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165056/ https://www.ncbi.nlm.nih.gov/pubmed/12823844 http://dx.doi.org/10.1186/ar759 |
| _version_ | 1782120827503771648 |
|---|---|
| author | Eisenberg, Robert |
| author_facet | Eisenberg, Robert |
| author_sort | Eisenberg, Robert |
| collection | PubMed |
| description | B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, and will teach us more about the roles of B cells in its pathogenesis. |
| format | Text |
| id | pubmed-165056 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2003 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-1650562003-07-12 SLE - Rituximab in lupus Eisenberg, Robert Arthritis Res Ther Commentary B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, and will teach us more about the roles of B cells in its pathogenesis. BioMed Central 2003 2003-04-15 /pmc/articles/PMC165056/ /pubmed/12823844 http://dx.doi.org/10.1186/ar759 Text en Copyright © 2003 BioMed Central Ltd |
| spellingShingle | Commentary Eisenberg, Robert SLE - Rituximab in lupus |
| title | SLE - Rituximab in lupus |
| title_full | SLE - Rituximab in lupus |
| title_fullStr | SLE - Rituximab in lupus |
| title_full_unstemmed | SLE - Rituximab in lupus |
| title_short | SLE - Rituximab in lupus |
| title_sort | sle - rituximab in lupus |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165056/ https://www.ncbi.nlm.nih.gov/pubmed/12823844 http://dx.doi.org/10.1186/ar759 |
| work_keys_str_mv | AT eisenbergrobert slerituximabinlupus |